文献速递胸部肿瘤

同步放化疗联合SBRT推量治疗不可切除Ⅲ期非小细胞肺癌的Ⅰ期研究

Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
PubMed 文献 · J Thorac Oncol · 2017-09-13

这项多机构Ⅰ期研究评估了44 Gy常规分割胸部放疗联合同步化疗后,对原发肿瘤及受累纵隔淋巴结行SBRT推量的安全性,主要终点为最大耐受剂量(MTD)。2012年11月至2016年12月共治疗15例不可切除ⅢA/ⅢB期NSCLC患者,计算MTD为6 Gy×5,但该剂量出现1例气管食管瘘;10 Gy×2剂量组未观察到3级及以上毒性,作者认为可考虑更安全。

要点

  • 计算MTD为6 Gy×5,但该剂量出现气管食管瘘,研究者不愿继续入组。
  • 10 Gy×2剂量组未观察到3级及以上毒性,作者认为可考虑更安全。
  • 剂量队列1和2无剂量限制性毒性,队列3有1例、队列4有2例。

核心结论

  • SBRT推量联合44 Gy胸部放化疗的MTD为6 Gy×5;10 Gy×2可考虑更安全,因该剂量随访期间未观察到3级及以上毒性。

研究设计与样本

  • 多机构Ⅰ期研究,纳入不可切除ⅢA或ⅢB期NSCLC,原发肿瘤≤8 cm,N1或N2淋巴结≤5 cm。
  • 治疗方案为44 Gy胸部放疗(2 Gy/天)联合每周卡铂和紫杉醇化疗,40 Gy后二次CT模拟定位,对原发灶及受累纵隔淋巴结残留大体肿瘤行SBRT推量。
  • SBRT推量设4个剂量队列:队列1(9 Gy×2)、队列2(10 Gy×5)、队列3(6 Gy×5)、队列4(7 Gy×5)。
  • 每队列3例患者,采用贝叶斯过量控制递增法确定MTD;剂量限制性毒性定义为治疗相关30天内任何≥3级非血液学毒性或任何治疗相关5级毒性。
  • 2012年11月至2016年12月入组19例,4例筛选失败,15例接受治疗。

主要发现

  • 剂量队列1(n=3)和队列2(n=6)无剂量限制性毒性。
  • 剂量队列3(n=3)有1例出现剂量限制性毒性,队列4(n=3)有2例出现剂量限制性毒性。
  • 计算MTD为6 Gy×5,该剂量观察到的剂量限制性毒性为气管食管瘘。
  • 因该显著毒性,研究者不愿在6 Gy×5剂量水平继续入组患者。
  • 10 Gy×2剂量组未发生5级毒性,作者认为该剂量也是合理选择。

关键数值与推荐

  • 计算MTD为6 Gy×5。
  • 10 Gy×2剂量组未观察到3级及以上毒性,作者认为可考虑更安全。

临床怎么用

  • 作者认为SBRT推量联合44 Gy胸部放化疗的MTD为6 Gy×5,但10 Gy×2可考虑更安全。

局限性

  • 6 Gy×5剂量水平出现气管食管瘘,研究者不愿继续入组。
  • 样本量小,15例接受治疗。
  • 原文未报告随访时长。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Stereotactic body radiation therapy (SBRT) is now the standard of care in medically inoperable stage I NSCLC, yielding high rates of local control. It is unknown whether SBRT can be safely utilized in the locally advanced NSCLC setting. This multi-institution phase I study evaluated the safety of 44 Gy of conventionally fractionated thoracic radiation with concurrent chemotherapy plus dose-escalated SBRT boost to both the primary tumor and involved mediastinal lymph nodes. The primary end point of this study was to establish the maximum tolerated dose (MTD) of the SBRT boost. METHODS: Inclusion criteria included unresectable stage IIIA or IIIB disease, primary tumor 8 cm or smaller, and N1 or N2 lymph nodes 5 cm or smaller. Tumors were staged with positron emission tomography/computed tomography (CT), and four-dimensional CT simulation was used for radiation planning. The treatment schema was 44 Gy of thoracic radiation (2 Gy/d) with weekly carboplatin and paclitaxel chemotherapy. A second CT simulation was obtained after 40 Gy had been delivered, and a SBRT boost was planned to the remaining gross disease at the primary site and involved mediastinal lymph nodes. Consolidation chemotherapy was given at the discretion of the treating medical oncologist. Four SBRT boost dose cohorts were tested: cohort 1 (9 Gy × 2), cohort 2 (10 Gy × 5), cohort 3 (6 Gy × 5), and cohort 4 (7 Gy × 5). Patients were treated in cohorts of three patients, and the Bayesian escalation with overdose control method was used to determine the MTD of the SBRT boost. Dose-limiting toxicities (DLTs) were defined as any grade 3 or higher toxicities within 30 days of treatment attributed to treatment, not including hematologic toxicity, or any grade 5 toxicity attributed to treatment. RESULTS: The study enrolled 19 patients from November 2012 to December 2016. There were four screen failures, and 15 patients were treated on study. There were no DLTs in dose cohort 1 (n = 3) and 2 (n = 6). DLT developed in one patient in dose cohort 3 (n = 3) and in 2 patients in dose cohort 4 (n = 3). The calculated MTD was 6 Gy × 5. The DLT observed at this dose level was a tracheoesophageal fistula; given this substantial toxicity, there was investigator reluctance to enroll further patients at this dose level. Thus, the calculated MTD was 6 Gy × 5; however, 10 Gy × 2 is thought to be a reasonable dose as well, given that no grade 5 toxicities occurred with that dose. CONCLUSIONS: The MTD of a SBRT boost combined with 44 Gy of thoracic chemoradiation was 6 Gy × 5. A SBRT boost dose of 10 Gy × 2 could be considered safer, with no grade 3 or higher toxicities observed at this dose level during the follow-up period in this study.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Higgins KA, Pillai RN, Chen Z, et al. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study. J Thorac Oncol. 2017. PMID: 28919394. doi:10.1016/j.jtho.2017.07.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。